Shopping Cart
Remove All
Your shopping cart is currently empty
Tremelimumab (Synonyms: Ticilimumab, CP-675206)
Catalog No. T77466 Copy Product Info
🥰Excellent
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Tremelimumab
Copy Product Info🥰Excellent
Catalog No. T77466
Synonyms Ticilimumab, CP-675206
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Cas No. 745013-59-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $155 | In Stock | In Stock | |
| 5 mg | $472 | In Stock | In Stock | |
| 10 mg | $690 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,460 | Inquiry | Inquiry | |
| 100 mg | $1,970 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.3% (SDS-PAGE); 98.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer. |
| In vitro | Tremelimumab exhibits a higher binding affinity for CTLA-4-Ig compared to CD28-Ig, demonstrating specificity for cynomolgus monkeys and humans. It does not engage with human leukocyte FcγR, mitigating the risk of cytokine release syndrome. Interestingly, Tremelimumab enhances IL-2 production in a concentration-dependent manner when stimulated with staphylococcal enterotoxin A, showcasing its ability to modulate T-cell responses.[1] |
| Synonyms | Ticilimumab, CP-675206 |
| Reactivity | Human |
| Verified Activity | Immobilized Human CTLA-4 Protein (His) (TMPY-04348) at 1 μg/mL (100 μL/well) can bind Tremelimumab. The EC50 is 0.630 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CTLA-4/CD152 |
| Molecular Weight | 146.3 kDa |
| Cas No. | 745013-59-6 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Tremelimumab | purchase Tremelimumab | Tremelimumab cost | order Tremelimumab | Tremelimumab chemical structure | Tremelimumab in vitro | Tremelimumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.